Drug firm Suven Life Sciences today reported 56 per cent rise in standalone net profit to Rs 62.51 crore for the March quarter.
It had posted a net profit of Rs 40.06 crore for the corresponding period of the previous fiscal, Suven Life Sciences said in a filing to BSE.
Its standalone revenue from operations rose to Rs 213.72 crore for the fourth quarter of 2017-18. The revenue was Rs 180.14 crore in Q4 of 2016-17.
For the entire fiscal ended March this year, the company posted a net profit of Rs 158.42 crore as against Rs 123.47 crore in the previous fiscal.
Suven's standalone total revenue from operations rose to Rs 625.25 crore for 2017-18. It was Rs 544.47 crore in 2016-17.
The company's stock was up 4.65 per cent at Rs 190.30 on BSE.
Disclaimer: No Business Standard Journalist was involved in creation of this content
You’ve reached your limit of {{free_limit}} free articles this month.
Subscribe now for unlimited access.
Already subscribed? Log in
Subscribe to read the full story →
Smart Quarterly
₹900
3 Months
₹300/Month
Smart Essential
₹2,700
1 Year
₹225/Month
Super Saver
₹3,900
2 Years
₹162/Month
Renews automatically, cancel anytime
Here’s what’s included in our digital subscription plans
Exclusive premium stories online
Over 30 premium stories daily, handpicked by our editors
Complimentary Access to The New York Times
News, Games, Cooking, Audio, Wirecutter & The Athletic
Business Standard Epaper
Digital replica of our daily newspaper — with options to read, save, and share
Curated Newsletters
Insights on markets, finance, politics, tech, and more delivered to your inbox
Market Analysis & Investment Insights
In-depth market analysis & insights with access to The Smart Investor
Archives
Repository of articles and publications dating back to 1997
Ad-free Reading
Uninterrupted reading experience with no advertisements
Seamless Access Across All Devices
Access Business Standard across devices — mobile, tablet, or PC, via web or app